The FDA Group’s CEO Nick Capman sits down with seasoned investor Salvatore Buscemi to delve into the intricacies of investment in early-stage life science and device companies. They highlight key aspects such as: » The definition and role of 'family offices' in life science investments. » The importance of investors being prepared to lose their investment due to potential risks, highlighting that these investors should be aware of who they're investing alongside. » The mistakes founders often make when raising capital, notably misunderstanding the relationship-driven nature of the business, and the need to build trust before expecting monetary investments. » The significance of startups communicating regularly with potential investors, setting investment deadlines, and offering additional rewards like advisory board positions. » The need to carefully consider going public, as it's not the only exit strategy and can necessitate a change in leadership. » Sal's recently published book "Investing Legacy," aimed at guiding newly wealthy individuals seeking to build a long-term legacy, and the importance of understanding different investment types. » Encouragement for new entrepreneurs to view entrepreneurship as self-development, predicting a resurgence in IPO markets and mergers in the next 12 to 18 months. Salvatore M. Buscemi has made a name for himself through his impressive portfolio of investments and his leadership roles in various investment offices. Currently serving as the CEO and Co-Founding Partner of HRN, LLC, a private multi-family investment office, as well as the CEO for Dandrew Partners Capital Management, Buscemi has demonstrated a keen eye for successful investment strategies. He also serves as the Managing Partner for several other direct investment vehicles, spanning multiple asset classes in commercial real estate and credit, fine art private credit facilities, special situations, and well-performing life sciences investments, among others. Who is The FDA Group? The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. https://www.thefdagroup.com/
Navigating Risk Management in Medical Devices with Brian Dense
The DEA, FDA & Controlled Substances: An Insider's Perspective with Former DEA Agent Dennis Wichern
A Deep Dive into Medical Device Regulatory Strategy with Regulatory Attorney Christine P. Bump
Lessons from a Medtech Entrepreneur: Ram Konduru on Fostering Teamwork and Personal Growth in Leadership
Unlocking Effective Leadership: A Conversation with MetaComet Systems President, David Marlin
Leadership, Management, and Enhancing Quality of Life: A Conversation with Dan Barker, CEO of Wikimotive
Navigating the 510(k) Process: A Q&A with Regulatory Consultant, Trey Thorsen, MS, RAC
The Future of Life Science Talent Acquisition: Securing In-Demand Skills in a Competitive Market
FDA Revives Its Proposed Quality Metrics Program for Pharma
Inspection Alternatives Are Driving More FDA Enforcement Actions: What It Means for Industry
FDA's Domestic Biopharma Inspections Return to Normal
Quality Management Review: Benchmarking Quantitatively!
Addressing FDA's Inspection Backlog with Mary Denigan-Macauley, GAO's Director of Health Care
FDA's Fraudulent Products Task Force and Operation Quack Hack Battle COVID Vaccine Scams
What to Expect for the FDA's Regulation of Medical Devices & Digital Health Under the Biden Administration
Clinical Outsourcing & Insourcing: Selecting the Right Model or Mix
What RA/QA/Clinical Leaders Should Expect From the FDA in 2021
Inside FDA Pre-Approval Inspections with Former FDA Investigator, Christopher Smith
A Look at FDA's Pandemic Inspections Q&A Guidance
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind